Faculty Collaboration Database

Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003 Feb;23(2):183-9

Date

02/18/2003

Pubmed ID

12587807

DOI

10.1592/phco.23.2.183.32082

Scopus ID

2-s2.0-0037318622 (requires institutional sign-in at Scopus site)   25 Citations

Abstract

Inhaled anticholinergic drugs are considered one of the principal bronchodilator treatments for chronic obstructive pulmonary disease (COPD). Ipratropium bromide is an anticholinergic drug frequently administered for the treatment of COPD. Unfortunately, ipratropium has a short duration of action, requiring administration every 6 hours; this regimen affects adherence to drug therapy. Tiotropium bromide is structurally similar to ipratropium and is under development in the United States. The duration of action of tiotropium is approximately 24 hours, allowing for once-daily dosing. Other than xerostomia being more common with tiotropium than with ipratropium, the safety profiles of these drugs were similar in studied populations. On the basis of its improvements in trough spirometric measurements and improved pharmacokinetic profile compared with that of ipratropium, tiotropium is likely to become the first-line anticholinergic agent in the treatment of patients with COPD.

Author List

Panning CA, DeBisschop M

Author

Michael Debisschop PharmD Professor in the School of Pharmacy Administration department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Administration, Inhalation
Cholinergic Antagonists
Drug Administration Schedule
Humans
Pulmonary Disease, Chronic Obstructive
Randomized Controlled Trials as Topic
Scopolamine Derivatives
Tiotropium Bromide